The BioCentury Europe index gained 13% in 2Q14, while the BioCentury London index gained 8%. Twelve of 19 continental European biotechs in the market cap-weighted European index advanced last quarter, led by a 34% increase in the value of Actelion Ltd. (SIX:ATLN) to €11.1 billion ($15.2 billion). Last quarter, the Swiss biotech reported that its twice-daily oral selexipag (ACT-293987) met the